Last reviewed · How we verify

DongE E Jiao Coporation Limited — Portfolio Competitive Intelligence Brief

DongE E Jiao Coporation Limited pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Wuzi Yanzong oral liquid Wuzi Yanzong oral liquid marketed Reproductive Health / Traditional Chinese Medicine
Guilu Erxian Oral Liquid Guilu Erxian Oral Liquid marketed Traditional Chinese Medicine / General Wellness
compound E Jiao Jiang(cEJJ) compound E Jiao Jiang(cEJJ) marketed Traditional Chinese Medicine / Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for DongE E Jiao Coporation Limited:

Cite this brief

Drug Landscape (2026). DongE E Jiao Coporation Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/donge-e-jiao-coporation-limited. Accessed 2026-05-17.

Related